Overview

A Study Of PF-06263507 In Patients With Advanced Solid Tumors

Status:
Terminated
Trial end date:
2015-06-29
Target enrollment:
0
Participant gender:
All
Summary
To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
PF-06263507
Criteria
Inclusion Criteria:

- Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
or for which no standard therapy is available.

- Performance Status of 0 or 1.

- Adequate bone marrow, kidney, liver, and heart function.

Exclusion Criteria:

- Brain metastases requiring steroids.

- Major surgery or anti-cancer therapy within 4 weeks of study treatment start.

- Active bacterial, fungal or viral infection.